Jean-Frédéric Blanc

2.0k total citations · 2 hit papers
9 papers, 1.3k citations indexed

About

Jean-Frédéric Blanc is a scholar working on Hepatology, Oncology and Epidemiology. According to data from OpenAlex, Jean-Frédéric Blanc has authored 9 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Hepatology, 3 papers in Oncology and 3 papers in Epidemiology. Recurrent topics in Jean-Frédéric Blanc's work include Hepatocellular Carcinoma Treatment and Prognosis (6 papers), Pancreatic and Hepatic Oncology Research (3 papers) and Cancer Mechanisms and Therapy (2 papers). Jean-Frédéric Blanc is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (6 papers), Pancreatic and Hepatic Oncology Research (3 papers) and Cancer Mechanisms and Therapy (2 papers). Jean-Frédéric Blanc collaborates with scholars based in France, United States and Germany. Jean-Frédéric Blanc's co-authors include Andrew X. Zhu, Masatoshi Kudo, Takuji Okusaka, Paolo Abada, Ian Chau, Baek‐Yeol Ryoo, Joon Oh Park, Túlio Pfiffer, Chia-Jui Yen and Davide Pastorelli and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and The Lancet Oncology.

In The Last Decade

Jean-Frédéric Blanc

9 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

2015 634 citations Andrew X. Zhu, Joon Oh Park et al. The Lancet Oncology profile →
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib

2014 449 citations Andrew X. Zhu, Masatoshi Kudo et al. JAMA profile →

Peers

Countries citing papers authored by Jean-Frédéric Blanc

Since Specialization

Citations

This map shows the geographic impact of Jean-Frédéric Blanc's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean-Frédéric Blanc with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean-Frédéric Blanc more than expected).

Fields of papers citing papers by Jean-Frédéric Blanc

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean-Frédéric Blanc. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean-Frédéric Blanc. The network helps show where Jean-Frédéric Blanc may publish in the future.

Co-authorship network of co-authors of Jean-Frédéric Blanc

This figure shows the co-authorship network connecting the top 25 collaborators of Jean-Frédéric Blanc. A scholar is included among the top collaborators of Jean-Frédéric Blanc based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean-Frédéric Blanc. Jean-Frédéric Blanc is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

#	Work	Indexed citations
1	ctDNA analysis of patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with lenvatinib (LEN) or sorafenib (SOR) as 1L therapy. 2024 ·Journal of Clinical Oncology ·T.R. Jeffry Evans, Masatoshi Kudo, Ann‐Lii Cheng, Lucjan Wyrwicz, Roger K.C. Ngan, Jean-Frédéric Blanc, Ari David Baron, Arndt Vogel, Masafumi Ikeda, Fabio Piscaglia, Shukui Qin, Taisuke Hoshi, (unknown), Yasuhiro Funahashi, Chinyere E. Okpara, Koji Sagane, Dongyuan Xing, Yukinori Minoshima, Richard S. Finn	1
2	Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1 2020 ·Pancreatology ·Li‐Tzong Chen, Teresa Macarulla, Jean-Frédéric Blanc, Beloo Mirakhur, Floris A. de Jong, Bruce Belanger, Tanios Bekaii‐Saab, Jens T. Siveke	8
3	Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials 2020 ·ESMO Open ·Andrew X. Zhu, Ryan David Nipp, Richard S. Finn, Peter R. Galle, Josep M. Llovet, Jean-Frédéric Blanc, Takuji Okusaka, Ian Chau, David Cella, Allicia C. Girvan, (unknown), Lee Bowman, Chunxiao Wang, Yanzhi Hsu, Paolo Abada, Masatoshi Kudo	21
4	Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study 2018 ·British Journal of Cancer ·Ian Chau, Joon Oh Park, Baek‐Yeol Ryoo, Chia-Jui Yen, Ronnie T.P. Poon, Davide Pastorelli, Jean-Frédéric Blanc, Masatoshi Kudo, Túlio Pfiffer, Etsuro Hatano, Hyun Cheol Chung, Kateřina Kopečková, Jean–Marc Phelip, Giovanni Brandi, Shinichi Ohkawa, Chung‐Pin Li, Takuji Okusaka, Yanzhi Hsu, Paolo Abada, Andrew X. Zhu	27
5	Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial 2018 ·European Journal of Cancer ·Li‐Tzong Chen, Jens T. Siveke, Andrea Wang‐Gillam, Chung‐Pin Li, G. Bodoky, Andrew Dean, Yan‐Shen Shan, Gayle Jameson, Teresa Macarulla, Kyung-Hun Lee, David Cunningham, Jean-Frédéric Blanc, Chang-Fang Chiu, Gilberto Schwartsmann, Fadi S. Braiteh, (unknown), Bruce Belanger, Floris A. de Jong, Richard Hubner	20
6	Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial breakdown → 2015 ·The Lancet Oncology ·Andrew X. Zhu, Joon Oh Park, Baek‐Yeol Ryoo, Chia-Jui Yen, Ronnie T. P. Poon, Davide Pastorelli, Jean-Frédéric Blanc, Hyun Cheol Chung, Ari David Baron, Túlio Pfiffer, Takuji Okusaka, Kateřina Kubáčková, Jörg Trojan, Javier Sastre, Ian Chau, Shao-Chun Chang, Paolo Abada, Ling Yang, Jonathan D. Schwartz, Masatoshi Kudo	634
7	Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis 2015 ·European Journal of Nuclear Medicine and Molecular Imaging ·Julien Edeline, Laurence Crouzet, Boris Campillo‐Gimenez, Yan Rolland, Marc Pracht, Anne Guillygomarc’h, Karim Boudjéma, Laurence Lenoir, Xavier Adhoute, Tanguy Rohou, Éveline Boucher, Bruno Clément, Jean-Frédéric Blanc, Étienne Garin	67
8	Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib breakdown → 2014 ·JAMA ·Andrew X. Zhu, Masatoshi Kudo, Eric Assénat, Stéphane Cattan, Yoon‐Koo Kang, Ho Yeong Lim, Ronnie T.P. Poon, Jean-Frédéric Blanc, Arndt Vogel, Chao‐Long Chen, Étienne Dorval, Markus Peck‐Radosavljevic, Armando Santoro, Bruno Daniele, Junji Furuse, Annette Jappe, Kevin Perraud, Oezlem Anak, Dalila Sellami, Li‐Tzong Chen	449
9	ESM-1 expression in stromal cells is predictive of recurrence after radiofrequency ablation in early hepatocellular carcinoma 2013 ·Journal of Hepatology ·Marianne Ziol, Angéla Sutton, Julien Caldéraro, Nathalie Barget, Mounir Aout, Vincent Leroy, Jean-Frédéric Blanc, Nathalie Stürm, Paulette Bioulac‐Sage, Pierre Nahon, Jean‐Charles Nault, Nathalie Charnaux, G. Nkontchou, Jean–Claude Trinchet, Maryse Delehedde, Olivier Séror, Michel Beaugrand, Éric Vicaut, Nathalie Ganne‐Carrié	34

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact